Rizzo, A.; Racca, M.; Albano, D.; Dondi, F.; Bertagna, F.; Annunziata, S.; Treglia, G.
Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis. Pharmaceuticals 2022, 15, 1368.
https://doi.org/10.3390/ph15111368
AMA Style
Rizzo A, Racca M, Albano D, Dondi F, Bertagna F, Annunziata S, Treglia G.
Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis. Pharmaceuticals. 2022; 15(11):1368.
https://doi.org/10.3390/ph15111368
Chicago/Turabian Style
Rizzo, Alessio, Manuela Racca, Domenico Albano, Francesco Dondi, Francesco Bertagna, Salvatore Annunziata, and Giorgio Treglia.
2022. "Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis" Pharmaceuticals 15, no. 11: 1368.
https://doi.org/10.3390/ph15111368
APA Style
Rizzo, A., Racca, M., Albano, D., Dondi, F., Bertagna, F., Annunziata, S., & Treglia, G.
(2022). Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis. Pharmaceuticals, 15(11), 1368.
https://doi.org/10.3390/ph15111368